Abstract
To date, the beta amyloid (Aβ) cascade hypothesis remains the main pathogenetic model of Alzheimers disease (AD), but its role in the majority of sporadic AD cases is unclear. The mitochondria play central role in the bioenergetics of the cell and apoptotic cell death. In the past 20 years research has been directed at clarifying the involvement of mitochondria and defects in mitochondrial oxidative phosphorylation in late-onset neurodegenerative disorders, including AD. Morphological, biochemical and genetic abnormalities of the mitochondria in several AD tissues have been reported. Impaired mitochondrial respiration, particularly COX deficiency, has been observed in brain, platelets and fibroblasts of AD patients. The “mitochondrial cascade hypothesis” could explain many of the biochemical, genetic and pathological features of sporadic AD. Somatic mutations in mitochondrial DNA (mtDNA) could cause energy failure, increased oxidative stress and accumulation of Aβ, which in a vicious cycle reinforces the mtDNA damage and the oxidative stress. Despite the evidence of mitochondrial dysfunction in AD, no causative mutations in the mtDNA have been detected so far. Indeed, results of studies on the role of mtDNA haplogroups in AD are controversial. In this review we discuss the role of the mitochondria in the cascade of events leading to AD, and we will try to provide an answer to the question “what comes first”.
Keywords: Alzheimer's disease, haplogroups, mitochondria, mtDNA, neurodegeneration
Current Alzheimer Research
Title: Mitochondria, Mitochondrial DNA and Alzheimers Disease. What Comes First?
Volume: 5 Issue: 5
Author(s): Michelangelo Mancuso, Daniele Orsucci, Gabiele Siciliano and Luigi Murri
Affiliation:
Keywords: Alzheimer's disease, haplogroups, mitochondria, mtDNA, neurodegeneration
Abstract: To date, the beta amyloid (Aβ) cascade hypothesis remains the main pathogenetic model of Alzheimers disease (AD), but its role in the majority of sporadic AD cases is unclear. The mitochondria play central role in the bioenergetics of the cell and apoptotic cell death. In the past 20 years research has been directed at clarifying the involvement of mitochondria and defects in mitochondrial oxidative phosphorylation in late-onset neurodegenerative disorders, including AD. Morphological, biochemical and genetic abnormalities of the mitochondria in several AD tissues have been reported. Impaired mitochondrial respiration, particularly COX deficiency, has been observed in brain, platelets and fibroblasts of AD patients. The “mitochondrial cascade hypothesis” could explain many of the biochemical, genetic and pathological features of sporadic AD. Somatic mutations in mitochondrial DNA (mtDNA) could cause energy failure, increased oxidative stress and accumulation of Aβ, which in a vicious cycle reinforces the mtDNA damage and the oxidative stress. Despite the evidence of mitochondrial dysfunction in AD, no causative mutations in the mtDNA have been detected so far. Indeed, results of studies on the role of mtDNA haplogroups in AD are controversial. In this review we discuss the role of the mitochondria in the cascade of events leading to AD, and we will try to provide an answer to the question “what comes first”.
Export Options
About this article
Cite this article as:
Mancuso Michelangelo, Orsucci Daniele, Siciliano Gabiele and Murri Luigi, Mitochondria, Mitochondrial DNA and Alzheimers Disease. What Comes First?, Current Alzheimer Research 2008; 5 (5) . https://dx.doi.org/10.2174/156720508785908946
DOI https://dx.doi.org/10.2174/156720508785908946 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serotonin 5-HT<sub>4</sub> Receptors: A New Strategy for Developing Fast Acting Antidepressants?
Current Pharmaceutical Design Pharmacologic Intervention in Axonal Excitability: In Vivo Assessment of Nodal Persistent Sodium Currents in Human Neuropathies
Current Molecular Pharmacology Podocyte Mitosis – A Catastrophe
Current Molecular Medicine PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research
Current Medicinal Chemistry Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry From the Editors Perspective: Rational Approaches for Radical Entities
Current Neurovascular Research Rationally Designed Multi-Targeted Agents Against Neurodegenerative Diseases
Current Medicinal Chemistry Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology Advanced Drug Delivery of N-Acetylcarnosine (N-Acetyl-beta-alanyl-Lhistidine), Carcinine (Beta-alanylhistamine) and L-carnosine (Beta-alanyl- L-histidine) in Targeting Peptide Compounds as Pharmacological Chaperones for Use in Tissue Engineering, Human Disease Management and Therapy: From in vitro to the Clinic
Recent Patents on Drug Delivery & Formulation From the Multifactorial Nature of Alzheimer`s Disease to Multitarget Therapy: The Contribution of the Translational Approach
Current Topics in Medicinal Chemistry Manipulating Kynurenic Acid Levels in the Brain – On the Edge Between Neuroprotection and Cognitive Dysfunction
Current Topics in Medicinal Chemistry Current Opinion on 3-[2-[(2-Tert-Butyl-Phenylaminooxalyl)-Amino]-Propionylamino]- 4-Oxo-5-(2,3,5,6-Tetrafluoro-Phenoxy)-Pentanoic Acid, an Investigational Drug Targeting Caspases and Caspase-Like Proteases: The Clinical Trials in Sight and Recent Anti-Inflammatory Advances
Recent Patents on Inflammation & Allergy Drug Discovery Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Editorial (Thematic Issue: Current Update on Association Between Alzheimer’s Disease and Type 2 Diabetes: Volume I)
CNS & Neurological Disorders - Drug Targets The Problem of Amino Acid Complementarity and Antisense Peptides
Current Protein & Peptide Science Molecular Cytogenetics and Cytogenomics of Brain Diseases
Current Genomics Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Conference Report
CNS & Neurological Disorders - Drug Targets Astrocytes Pathology in ALS: A Potential Therapeutic Target?
Current Pharmaceutical Design Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets